Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2CR0K
|
|||
| Drug Name |
NK100
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 1 | [1] | |
| Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
Fate Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03081780) Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03319459) FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.